ALXO

ALX Oncology Holdings Inc. is a pioneering clinical-stage immuno-oncology company based in Burlingame, California, dedicated to discovering and developing novel therapies that harness the immune system to combat cancer. The company's unique approach focuses on targeting essential mechanisms within tumor biology, employing advanced immune modulation to improve patient outcomes. With a robust pipeline of promising therapeutic candidates, ALX Oncology presents a compelling investment opportunity for institutional investors looking to strategically engage in the evolving landscape of oncology therapies.